New Insights into Anti-cancer Drug Discovery and Development
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 2179
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer drug discovery has greatly advanced since its earliest steps. However, rare occurrences of anti-cancer drug-resistant cancer show a poor prognosis via recurrence or metastasis, and these consequences can be associated with patient death. Various studies have shown that recurrent or metastatic cancer is refractory to most medical treatments. These refractory cancers are usually slow; however, following anaplasia of the injury, they are altered into poorly differentiated and undifferentiated cancer, described by a sharp expansion involving a poor prognosis. The stemness and aggressiveness of refractory cancer has not yet been revealed. Studies looking at the outcomes from the advancement of anti-cancer drugs have described that pre-operative chemotherapy can extend survival rates after surgery. Nonetheless, no selective therapeutic options have been accepted as the basal adjuvant or neoadjuvant background for drug-resistant cancer, and a substantial number of anti-cancer drug-resistant cancer patients have died; therefore, unmet medical needs have consistently increased. Refractory cancer due to drug resistance, which mediates metastasis and recurrence, is a decisive part of unmet medical needs. Anti-cancer drug resistance remains a fundamental challenge in the treatment of patients with refractory cancer. For these reasons, anti-cancer drug resistance in refractory cancer represents a primary challenge in cancer therapy. Submission to this Special Issue could be potentially exploited as a breakthrough clinical solution to drug-resistant cancer.
Dr. Ki-cheong Park
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anti-cancer drug resistant
- cancer recurrence
- cancer metastasis
- cancer stem cells
- target validation
- target identification
- metabolic reprogramming of cancer stem cells
- unmet medical needs
